Menu Display

Breadcrumb

HER2 in Gynecologic Cancers—Why It Matters

In certain cancers, HER2 becomes overexpressed or uncontrolled, driving tumors to develop quickly.  As our understanding of HER2 and its role deepens, its relevance across endometrial, ovarian and other gynecologic tumors has become…

 

Illustration of the female reproductive system with highlighted areas indicating cancer sites, alongside the text ‘Treatment Innovations in Gynecologic Cancers

Category Filter

Asset Publisher

Content with Our Story Innovation .

HER2 in Gynecologic Cancers—Why It Matters
HER2 in Gynecologic Cancers—Why It Matters

In certain cancers, HER2 becomes overexpressed or uncontrolled, driving tumors to develop quickly. As our understanding of HER2 and its role deepens, its relevance across endometrial, ovarian and other gynecologic tumors has become…

Turning Complexity into Hope in Honor of My Father
Turning Complexity into Hope in Honor of My Father

My decision to devote my career to oncology is deeply personal. During my senior year in college, my father was diagnosed with cholangiocarcinoma, or bile duct cancer. As one of his caregivers…

Understanding Metastatic Breast Cancer: Exploring the Science
Understanding Metastatic Breast Cancer: Exploring the Science

Not all breast cancers are the same. This is particularly true about metastatic breast cancer versus early-stage breast cancer in terms of how the disease spreads, its prognosis, treatment options, and even the patient journey.

Crafting Meaningful Connections to Benefit Patients
Crafting Meaningful Connections to Benefit Patients

Business development is the craft of making connections. Whether with other companies or within our organization, we need to build those bonds that allow us to be successful. 

Beyond Positive & Negative: The Spectrum of HER2 Expression in Cancer
Beyond Positive & Negative: The Spectrum of HER2 Expression in Cancer

Cancer research and development is a dynamic and ever-evolving field. One significant area of focus is the role of HER2.

Daiichi Sankyo’s HER2 Directed ADC Receives Industry’s Top Award
Daiichi Sankyo’s HER2 Directed ADC Receives Industry’s Top Award

The Galien Foundation has recognized Daiichi Sankyo’s HER2 directed antibody drug conjugate (ADC) with the prestigious 2024 Prix Galien USA Award for Best Biotechnology Product.